Top Suppliers:I want be here
Related CAS#:
849235-66-1 849236-67-5
849236-44-8 849236-35-7
849236-70-0 849235-54-7
618888-20-3 1404561-05-2
953434-34-9 143239-24-1

66085-59-4

66085-59-4 structure
66085-59-4 structure
  • Name: Nimodipine
  • Chemical Name: nimodipine
  • CAS Number: 66085-59-4
  • Molecular Formula: C21H26N2O7
  • Molecular Weight: 418.440
  • Catalog: API Circulatory system medication Prevention and treatment of angina pectoris
  • Create Date: 2018-02-08 08:00:00
  • Modify Date: 2026-07-23 19:55:56
  • Nimodipine(Nimotop) is a dihydropyridine derivative and an analogue of the calcium channel blocker nifedipine, with antihypertensive activity.Nimodipine decreases intracellular free Ca2+,Beclin-1 and autophagy.Target: Calcium ChannelNimodipine is main use is in the prevention of cerebral vasospasm and resultant ischemia, a complication of subarachnoid hemorrhage (a form of cerebral bleed), specifically from ruptured intracranial berry aneurysms irrespective of the patient's post-ictus neurological condition. Its administration begins within 4 days of a subarachnoid hemorrhage and is continued for three weeks. If blood pressure drops by over 5%, dosage is adjusted. There is still controversy regarding the use of intravenous nimodipine on a routine basis [1, 2].
Name nimodipine
Synonyms Isopropyl 2-Methoxyethyl 1,4-Dihydro-2,6-dimethyl-4-(3-nitrophenyl)-3,5-pyridinedicboxylate
1-methylethyl 2-(methyloxy)ethyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate
1,4-DIHYDRO-2,6-DIMETHYL-4-(3'-NITROPHENYL)-3,5-PYRIDINEDICBOXYLIC ACID 2-METHOXYETHYL-1-METHYLETHYL ESTER
Isopropyl 2-methoxyethyl 1,4-dihydro-2,6-dimethyl-4-(m-nitrophenyl)-3,5-pyridinedicboxylate, 1,4-Dihydro-2,6-dimethyl-4-(3-nitrophenyl)-3,5-pyridinedicboxylic acid 2-methoxyethyl 1-methylethyl ester
3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-, 2-methoxyethyl 1-methylethyl ester
NiModipine(NiMotop)
PERIPLUM
Nimodipine BP
Nimodipine>
(4R)-2,6-dimethyl-4-(3-nitrophenyl)-3,4-dihydropyridine-3,5-dicboxylic acid O3-(2-methoxyethyl) ester O5-propan-2-yl ester
2，6-Dimethyl-4-(3-nitrophenyl)-1，4-dihydro-3，5-pyridinedicboxylic acid 2-methoxyethyl 1-methylethyl ester
Nimodipin
NIMODIPINE
NIMODIPINE ASSAY STANDD BP(CRM STANDD)
Nimodipine, >=
nimodipine api
Nimodipime
NIMODIPINE MM(CRM STANDD)
(R)-3-isopropyl 5-(2-methoxyethyl) 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicboxylate
3,5-Pyridinedicboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-, 2-methoxyethyl 1-methylethyl ester
NIMODIPINE CALCIUM CHANNEL ANTAG
Nimodipine //BP
Isopropyl 2-Methoxyethyl 1,4-Dihydro-2,6-dimethyl-4-(3-nitrophenyl)-3,5-pyridinedicarboxylate
2,6-Dimethyl-4-(3'-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylic Acid 3-b-Methoxyethyl Ester 5-Isopropyl Ester
Isopropyl 2-methoxyethyl
Isopropyl 2-methoxyethyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate
nimodipino
2-Methoxyethyl-1-methylethyl-2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridin-3,5-dicarboxylat
O5-(2-Methoxyethyl) O3-propan-2-yl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicboxylate
1,4-Dihydro-2,6-dimethyl-4-(3-nitrophenyl)-3,5 pyridinedicboxylic acid 2-methyloxyethyl 1-methylethyl ester
1,4-Dihydro-2,6-diMethyl-4-(3-nitrophenyl)
Bay e 9736, Admon, Nimotop, periplum
NIMODIPINE BP STANDD(CRM STANDD)
2,6-diméthyl-4-(3-nitrophényl)-1,4-dihydropyridine-3,5-dicarboxylate de 2-méthoxyéthyle et de 1-méthyléthyle
Nimodipine CRS
Isopropyl 2-methoxyethyl 1,4-dihydro-2,6-dimethyl-4-(m-nitrophenyl)-3,5-pyridinedicarboxylate
1,4-Dihydro-2,6-dimethyl-4-(3-ni-trophenyl)-3,5-pyridinedicboxylicacid
1,4-DIHYDRO-2,6-DIMETHYL-4-(3-NITROPHENYL)-3,5-PYRIDINEDICBOXYLIC ACID 2-METHYLOXYETHYL 1-METHYLETHYL ESTER
ethoxyethyl1-methylethylester
2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicboxylic acid O3-isopropyl O5-(2-methoxyethyl) ester
1,4-DIHYDRO-2,6-DIMETHYL-4-(3-NITROPHENYL)-3,5-PYRIDINEDICBOXYLIC ACID 2-METHOXYETHYL 1-METHYLETHYL ESTER
3-isopropyl 5-(2-Methoxyethyl) 2,6-diMethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicboxylate
inedicboxylate
1,4-Dihydro-2,6-dimethyl-4-(3-nitrophenyl)pyridine-3,5-dicboxylic acid 3-isopropyl 5-(2-methoxyethyl) ester
NimodipineQ: What is Nimodipine Q: What is the CAS Number of Nimodipine Q: What is the storage condition of Nimodipine Q: What e the applications of Nimodipine
Isopropyl 2-methoxyethyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicboxylate
3,5-Pyridinedicboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-, 3-(2-methoxyethyl) 5-(1-methylethyl) ester
Isopropyl 2-methoxyethyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydro-3,5-pyridinedicarboxylate
Nimodipine an analogue of the calcium channel blocker nifedipine
1-methylethyl 2-(methyloxy)ethyl 2,6-dimethyl-4-(3-nitroph
ADMON
BAY E
Nimodipine - - Calbiochem
NIMODIPINE N(CRM STANDD)
NIMOTOP
1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-3,5-pyridinedicboxylic acid- 3-(2-methoxyethyl) 5-(1-methylethyl) ester
MFCD00153848
Nimodipine (USAN/INN)
Nimodipine for peak identification
nimodipinum
NIMODIPINE(PATENT-NOSUPPLY)
Nimodipine,1,4-Dihydro-2,6-dimethyl-4-(3-nitrophenyl)-3,5-pyridinedicboxylic acid 2-methoxyethyl 1-methylethyl ester, Isopropyl 2-methoxyethyl 1,4-dihydro-2,6-dimethyl-4-(m-nitrophenyl)-3,5-pyridine
EINECS 266-127-0
isopropyl 2-methoxyethyl 1,4-dihydro-2,6-dimethyl-4-(m-nitrophenyl)-3,5-pyridinedicboxylate
O3-isopropyl O5-(2-methoxyethyl) 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicboxylate
2-methoxyethyl 1-methylethyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate
isopropyl2-methoxyethyl1,4-dihydro-2,6-dimethyl-4-(m-nitrophenyl)-3,5-pyrid
2-Methoxyethyl 14-Dihydro-5-(isopropoxycarbonyil)-2,6-dimethyl-4-(3-nitrophenyl)-3-pyridinecarboxylate
1,4-Dihydro-2,6-dimethyl-4-(3-nitrophenyl)-3,5-pyridinedicboxylic acid 3-isopropyl 5-(2-methoxyethyl) ester
UNII:57WA9QZ5WH
2-methyo-xyethyl 1-methylethyl ester
Description Nimodipine(Nimotop) is a dihydropyridine derivative and an analogue of the calcium channel blocker nifedipine, with antihypertensive activity.Nimodipine decreases intracellular free Ca2+,Beclin-1 and autophagy.Target: Calcium ChannelNimodipine is main use is in the prevention of cerebral vasospasm and resultant ischemia, a complication of subarachnoid hemorrhage (a form of cerebral bleed), specifically from ruptured intracranial berry aneurysms irrespective of the patient's post-ictus neurological condition. Its administration begins within 4 days of a subarachnoid hemorrhage and is continued for three weeks. If blood pressure drops by over 5%, dosage is adjusted. There is still controversy regarding the use of intravenous nimodipine on a routine basis [1, 2].
Related Catalog
References

[1]. Janjua, N. and S.A. Mayer, Cerebral vasospasm after subarachnoid hemorrhage. Curr Opin Crit Care, 2003. 9(2): p. 113-9.

[2]. Allen, G.S., et al., Cerebral arterial spasm--a controlled trial of nimodipine in patients with subarachnoid hemorrhage. N Engl J Med, 1983. 308(11): p. 619-24.
Density 1.2±0.1 g/cm3
Boiling Point 534.8±50.0 °C at 760 mmHg
Melting Point 125°C
Molecular Formula C21H26N2O7
Molecular Weight 418.440
Flash Point 277.3±30.1 °C
Exact Mass 418.174011
PSA 119.68000
LogP 3.86
Vapour Pressure 0.0±1.4 mmHg at 25°C
Index of Refraction 1.539
Storage condition Store at RT
Water Solubility methanol: 62.5 mg/mL

CHEMICAL IDENTIFICATION

RTECS NUMBER :
US7975500
CHEMICAL NAME :
3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-, 2-methoxyethyl 1-methylethyl ester
CAS REGISTRY NUMBER :
66085-59-4
LAST UPDATED :
199706
DATA ITEMS CITED :
15
MOLECULAR FORMULA :
C21-H26-N2-O7
MOLECULAR WEIGHT :
418.49

HEALTH HAZARD DATA

ACUTE TOXICITY DATA

TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Rodent - rat
DOSE/DURATION :
2738 mg/kg
TOXIC EFFECTS :
Behavioral - somnolence (general depressed activity) Gastrointestinal - hypermotility, diarrhea Nutritional and Gross Metabolic - body temperature decrease
REFERENCE :
KSRNAM Kiso to Rinsho. Clinical Report. (Yubunsha Co., Ltd., 1-5, Kanda Suda-Cho, Chiyoda-ku, KS Bldg., Tokyo 101, Japan) V.1- 1960- Volume(issue)/page/year: 19,6899,1985
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Subcutaneous
SPECIES OBSERVED :
Rodent - rat
DOSE/DURATION :
4234 mg/kg
TOXIC EFFECTS :
Behavioral - somnolence (general depressed activity)
REFERENCE :
KSRNAM Kiso to Rinsho. Clinical Report. (Yubunsha Co., Ltd., 1-5, Kanda Suda-Cho, Chiyoda-ku, KS Bldg., Tokyo 101, Japan) V.1- 1960- Volume(issue)/page/year: 19,6899,1985
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Intravenous
SPECIES OBSERVED :
Rodent - rat
DOSE/DURATION :
5 mg/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
REFERENCE :
ARTODN Archives of Toxicology. (Springer-Verlag, Heidelberger Pl. 3, D-1000 Berlin 33, Fed. Rep. Ger.) V.32- 1974- Volume(issue)/page/year: 54,275,1983
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Rodent - mouse
DOSE/DURATION :
940 mg/kg
TOXIC EFFECTS :
Behavioral - altered sleep time (including change in righting reflex) Behavioral - somnolence (general depressed activity) Nutritional and Gross Metabolic - body temperature decrease
REFERENCE :
KSRNAM Kiso to Rinsho. Clinical Report. (Yubunsha Co., Ltd., 1-5, Kanda Suda-Cho, Chiyoda-ku, KS Bldg., Tokyo 101, Japan) V.1- 1960- Volume(issue)/page/year: 19,6899,1985
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Subcutaneous
SPECIES OBSERVED :
Rodent - mouse
DOSE/DURATION :
9500 mg/kg
TOXIC EFFECTS :
Behavioral - somnolence (general depressed activity)
REFERENCE :
KSRNAM Kiso to Rinsho. Clinical Report. (Yubunsha Co., Ltd., 1-5, Kanda Suda-Cho, Chiyoda-ku, KS Bldg., Tokyo 101, Japan) V.1- 1960- Volume(issue)/page/year: 19,6899,1985
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Intravenous
SPECIES OBSERVED :
Rodent - mouse
DOSE/DURATION :
26200 ug/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
REFERENCE :
KSRNAM Kiso to Rinsho. Clinical Report. (Yubunsha Co., Ltd., 1-5, Kanda Suda-Cho, Chiyoda-ku, KS Bldg., Tokyo 101, Japan) V.1- 1960- Volume(issue)/page/year: 19,6899,1985
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Mammal - dog
DOSE/DURATION :
1 gm/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
REFERENCE :
KSRNAM Kiso to Rinsho. Clinical Report. (Yubunsha Co., Ltd., 1-5, Kanda Suda-Cho, Chiyoda-ku, KS Bldg., Tokyo 101, Japan) V.1- 1960- Volume(issue)/page/year: 19,6899,1985
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Intravenous
SPECIES OBSERVED :
Mammal - dog
DOSE/DURATION :
4 mg/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
REFERENCE :
ARZNAD Arzneimittel-Forschung. Drug Research. (Editio Cantor Verlag, Postfach 1255, W-7960 Aulendorf, Fed. Rep. Ger.) V.1- 1951- Volume(issue)/page/year: 36,1733,1986
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Rodent - rabbit
DOSE/DURATION :
5 gm/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
REFERENCE :
ARZNAD Arzneimittel-Forschung. Drug Research. (Editio Cantor Verlag, Postfach 1255, W-7960 Aulendorf, Fed. Rep. Ger.) V.1- 1951- Volume(issue)/page/year: 36,1733,1986
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Intravenous
SPECIES OBSERVED :
Rodent - rabbit
DOSE/DURATION :
2500 ug/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
REFERENCE :
ARZNAD Arzneimittel-Forschung. Drug Research. (Editio Cantor Verlag, Postfach 1255, W-7960 Aulendorf, Fed. Rep. Ger.) V.1- 1951- Volume(issue)/page/year: 36,1733,1986 ** OTHER MULTIPLE DOSE TOXICITY DATA **
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Rodent - rat
DOSE/DURATION :
9100 mg/kg/13W-C
TOXIC EFFECTS :
Liver - changes in liver weight Kidney, Ureter, Bladder - other changes in urine composition Blood - changes in platelet count
REFERENCE :
KSRNAM Kiso to Rinsho. Clinical Report. (Yubunsha Co., Ltd., 1-5, Kanda Suda-Cho, Chiyoda-ku, KS Bldg., Tokyo 101, Japan) V.1- 1960- Volume(issue)/page/year: 19,6907,1985
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Rodent - rat
DOSE/DURATION :
78840 mg/kg/2Y-C
TOXIC EFFECTS :
Behavioral - fluid intake Kidney, Ureter, Bladder - changes in bladder weight
REFERENCE :
ARZNAD Arzneimittel-Forschung. Drug Research. (Editio Cantor Verlag, Postfach 1255, W-7960 Aulendorf, Fed. Rep. Ger.) V.1- 1951- Volume(issue)/page/year: 36,1733,1986
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Mammal - dog
DOSE/DURATION :
2700 mg/kg/90D-C
TOXIC EFFECTS :
Kidney, Ureter, Bladder - other changes
REFERENCE :
KSRNAM Kiso to Rinsho. Clinical Report. (Yubunsha Co., Ltd., 1-5, Kanda Suda-Cho, Chiyoda-ku, KS Bldg., Tokyo 101, Japan) V.1- 1960- Volume(issue)/page/year: 19,6933,1985 ** REPRODUCTIVE DATA **
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
DOSE :
528 mg/kg
SEX/DURATION :
female 1-22 day(s) after conception lactating female 22 day(s) post-birth
TOXIC EFFECTS :
Reproductive - Specific Developmental Abnormalities - cardiovascular (circulatory) system
REFERENCE :
TCMUD8 Teratogenesis, Carcinogenesis, and Mutagenesis. (Alan R. Liss, Inc., 41 E. 11th St., New York, NY 10003) V.1- 1980- Volume(issue)/page/year: 9,39,1989
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
DOSE :
132 mg/kg
SEX/DURATION :
female 1-22 day(s) after conception lactating female 22 day(s) post-birth
TOXIC EFFECTS :
Reproductive - Specific Developmental Abnormalities - blood and lymphatic systems (including spleen and marrow)
REFERENCE :
TCMUD8 Teratogenesis, Carcinogenesis, and Mutagenesis. (Alan R. Liss, Inc., 41 E. 11th St., New York, NY 10003) V.1- 1980- Volume(issue)/page/year: 9,39,1989
Symbol GHS08
GHS08
Signal Word Warning
Hazard Statements H373
Precautionary Statements P260
Personal Protective Equipment dust mask type N95 (US);Eyeshields;Gloves
Hazard Codes Xn:Harmful
Risk Phrases R20/21/22
Safety Phrases S36
RIDADR NONH for all modes of transport
WGK Germany 1
RTECS US7975500
HS Code 2933990090
40100-28-5 structure

40100-28-5

39562-22-6 structure

39562-22-6

~80%

66085-59-4 structure

66085-59-4

Literature: Meyer; Wehinger; Bossert; Scherling Arzneimittel-Forschung/Drug Research, 1983 , vol. 33, # 1 p. 106 - 112
22502-03-0 structure

22502-03-0

~%

66085-59-4 structure

66085-59-4

Literature: Arzneimittel-Forschung/Drug Research, , vol. 33, # 1 p. 106 - 112
22502-03-0 structure

22502-03-0

99-61-6 structure

99-61-6

143093-33-8 structure

143093-33-8

~70%

66085-59-4 structure

66085-59-4

Detail
Literature: Yiu, Sai-Hay; Knaus, Edward E. Archiv der Pharmazie, 1997 , vol. 330, # 1-2 p. 35 - 43
542-08-5 structure

542-08-5

~%

66085-59-4 structure

66085-59-4

Literature: Arzneimittel-Forschung/Drug Research, , vol. 33, # 1 p. 106 - 112
542-08-5 structure

542-08-5

22502-03-0 structure

22502-03-0

99-61-6 structure

99-61-6

~%

66085-59-4 structure

66085-59-4

Literature: Journal of Organic Chemistry, , vol. 61, # 3 p. 924 - 928
HS Code 2933990090
Summary 2933990090. heterocyclic compounds with nitrogen hetero-atom(s) only. VAT:17.0%. Tax rebate rate:13.0%. . MFN tariff:6.5%. General tariff:20.0%
The content on this webpage is sourced from various professional data sources. If you have any questions or concerns regarding the content, please feel free to contact service1@chemsrc.com.

Chemsrc provides CAS#:66085-59-4 MSDS, density, melting point, boiling point, structure, formula, molecular weight, synthetic route, etc.
title: CAS No. 66085-59-4 | Chemsrc address: https://m.chemsrc.com/en/baike/832487.html

Home | MSDS/SDS Database Search | Journals | Product Classification | Biologically Active Compounds | Selling Leads | About Us | Disclaimer

Copyright © 2026 ChemSrc All Rights Reserved